Skip to content
Search

Latest Stories

Pharmacy bodies call for nationwide free Emergency Hormonal Contraception Service

Pharmacy bodies call for nationwide free Emergency Hormonal Contraception Service

EHC services are currently provided by an estimated 90% of local authorities in England, but only about 48% of community pharmacies are involved in these programmes

In a unified effort to improve women’s healthcare, four leading organisations—the Company Chemists’ Association (CCA), the National Pharmacy Association (NPA), the Royal Pharmaceutical Society (RPS), and the Faculty of Sexual and Reproductive Healthcare (FSRH)—are calling for the commissioning of a National Emergency Hormonal Contraception (EHC) service in England.


They are proposing that this service be provided free of charge through community pharmacies to women of all ages across the country.

They emphasised that such a service would “not only transform access to care for all women, but directly tackle health inequalities and vastly improve health outcomes.”

Ending the postcode lottery

The pharmacy bodies have also highlighted the need to end the "postcode lottery" that currently restricts equal access to these services.

They pointed out that EHC services are already widely commissioned by an estimated 90 per cent of local authorities in England, but only around 48 per cent of community pharmacies are included in these services.

Moreover, the lack of standardization and local variations in service provision mean that access to EHC services can depend heavily on one's postcode.

Some pharmacies have to determine the level of care they can offer to a woman based on the patient's postcode.

“Patchy and inconsistent local commissioning has created a postcode lottery of access for a service which clearly has significant national demand,” they noted.

Therefore, the CCA, NPA, RPS and FSRH are urging the government to eliminate this postcode lottery and ensure that all women, regardless of age, can access a nationally commissioned EHC service at their local community pharmacy.

Highlighting key issues with the current arrangements, they noted “an incomplete understanding of the availability of free at-the point access EHC services.”

Furthermore, they pointed out that since these services are commissioned by local authorities, they cannot be promoted nationally; and there are no national standards and training requirements for pharmacists and pharmacy teams to support the service.

All of these issues, they argued, could be resolved through the commissioning of a nationwide EHC service, mirroring the successful approaches adopted in Scotland and Wales.

EHC services in Scotland and Wales 

For many years, national EHC services have been commissioned in Scotland and Wales, leading to significantly fewer women seeking EHC from General Practice and resulting in lower abortion rates per 10,000 female population in both nations.

Despite a growing number of innovative routes to purchase EHC through pharmacies, including online private pharmacies, the organisations stressed that the greatest barrier to accessing the service and tackling health inequalities remains the cost.

“NHS commissioned services, free at the point of use, would ensure that women who need the service, can access it with ease, irrespective of their personal circumstances,” they stated.

The CCA, NPA, RPS, and FSRH are urging the government and the NHS to follow the successful examples set by Wales and Scotland and commission a national advanced EHC service in England.

They believe that additional investment in EHC and contraception services through community pharmacy would support the newly published Women’s Health Strategy, whilst also dramatically improving access, and setting higher standards of care across the country.

Unplanned pregnancies are more prevalent in areas with higher deprivation, they highlighted, citing the Department of Health & Social Care data indicating that girls, adolescents, and women in the most deprived areas are more than two times more likely to have a termination than those in the least deprived.

They warned that unplanned pregnancies may lead to an increased risk of adverse health outcomes.

Acknowledging the issue, NHS England recently launched a Pharmacy Contraception Service, enabling women to obtain the oral contraceptive pill free of charge and further expanding the role of pharmacies in women’s health.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less